company background image
5RT logo

Rubius Therapeutics DB:5RT Stock Report

Last Price

€0.013

Market Cap

€1.7m

7D

0%

1Y

n/a

Updated

12 Jun, 2023

Data

Company Financials

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

5RT Stock Overview

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases.

5RT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rubius Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Rubius Therapeutics
Historical stock prices
Current Share PriceUS$0.013
52 Week HighUS$1.40
52 Week LowUS$0.013
Beta2.39
1 Month Change0%
3 Month Change-23.53%
1 Year Changen/a
3 Year Change-99.75%
5 Year Changen/a
Change since IPO-99.94%

Recent News & Updates

Recent updates

Shareholder Returns

5RTDE BiotechsDE Market
7D0%2.1%1.9%
1Yn/a37.0%7.3%

Return vs Industry: Insufficient data to determine how 5RT performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 5RT performed against the German Market.

Price Volatility

Is 5RT's price volatile compared to industry and market?
5RT volatility
5RT Average Weekly Movementn/a
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 5RT's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 5RT's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20136Craig Jalberthttps://www.rubiustx.com

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

Rubius Therapeutics, Inc. Fundamentals Summary

How do Rubius Therapeutics's earnings and revenue compare to its market cap?
5RT fundamental statistics
Market cap€1.73m
Earnings (TTM)-€167.23m
Revenue (TTM)n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
5RT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$179.67m
Earnings-US$179.67m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.99
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 5RT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.